<DOC>
	<DOCNO>NCT00002427</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness 9 dos HU order find best dose HU use ddI d4T fight HIV infection . HU plus ddI plus d4T appear suitable anti-HIV drug combination long-term control HIV . This combination sharply decrease viral load ( level HIV body ) side effect , make easy take .</brief_summary>
	<brief_title>Safety Effectiveness Combining Hydroxyurea ( HU ) With Didanosine ( ddI ) Stavudine ( d4T ) Treatment HIV-Infected Adults</brief_title>
	<detailed_description>The combination HU plus ddI plus d4T appear suitable long-term control HIV : ( 1 ) novel resistance/rebound profile demonstrate virus suppression even presence ddI-resistant mutant ; ( 2 ) produce pronounce fall viral load ; ( 3 ) well tolerate ( 200 patient treat 3 year minimal side effect ) . Patients stratified antiretroviral experience : naive ( 2 week therapy ) versus experience ( 2 week ) . Patients must discontinue antiretroviral therapy least 28 day prior randomization 1 9 HU treatment arm . Treatment arm divide 3 HU dose category : low , low , medium . Within category HU administer daily 3 different dose schedule . Depending viral load , patient low low dose arm may opportunity intensify HU dose time beyond Week 12 , provide Grade 3 4 HU-related toxicity present ( patient monitor additional 8 week follow intensification ) . All patient receive ddI d4T dos every day . When 50 % patient complete 24 week treatment , analysis make determine whether continue 52-week study without modification . Patients monitor periodically change plasma HIV RNA , CD4 cell count , weight , symptom .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load 5,000 100,000 copies/ml . Are willing stop antiHIV medication least 28 day receive study drug . Are least 18 year old . Exclusion Criteria Patients eligible study : Have history opportunistic ( AIDSrelated ) infection . Have history pancreatitis serious condition . Have cancer require chemotherapy within next 24 week . Are allergic ddI d4T . Have receive HIV vaccine within 28 day study entry . Have receive red blood cell transfusion within past 60 day , repeat transfusion time past . Abuse alcohol drug . Have receive certain medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>